Press Release: Novartis presents new five-year -2-

pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About 106,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more at https://www.novartis.com

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews https://twitter.com/novartisnews

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

References

1. Cohen JA, Hauser SL, Zielman R, et al. Effect of Longer-term Ofatumumab

Treatment on Disability Worsening and Brain Volume Change. Oral

presentation at the American Academy of Neurology (AAN) 2023; April

22-27, 2023; Boston, MA.

2. Cohen JA, Hauser SL, Cross AH, et al. Five-Year Safety of Ofatumumab in

People Living With Relapsing Multiple Sclerosis. Poster presentation at

the American Academy of Neurology (AAN) 2023; April 22-27, 2023; Boston,

MA.

3. Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in

Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557.

doi:10.1056/NEJMoa1917246

4. Guthrie EW. Multiple sclerosis: A primer and update. Adv Studies Pharm.

2007;4(11):313-317.

5. Multiple Sclerosis International Federation. Atlas of MS 2013-Mapping

Multiple Sclerosis Around the World. Accessed August 12,

2020. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf

6. National MS Society. Types of MS. Accessed January 18, 2023.

https://www.nationalmssociety.org/What-is-MS/Types-of-MS

7. Kesimpta Prescribing Information. East Hanover, NJ: Novartis

Pharmaceuticals Corp; August 2020.

8. Bar-Or A, Fox E, Goodyear A, et al. Onset of B-cell depletion with

subcutaneous administration of ofatumumab in relapsing multiple

sclerosis: results from the APLIOS bioequivalence study. Poster

presentation at: ACTRIMS; February 2020; West Palm Beach, FL.

9. Smith P, Kakarieka A, Wallstroem E. Ofatumumab is a fully human anti-CD20

antibody achieving potent B-cell depletion through binding a distinct

epitope. Poster presentation at: ECTRIMS; September 2016; London, UK.

10. Smith P, Huck C, Wegert V, et al. Low-dose, subcutaneous anti-CD20

therapy effectively depletes B-cells and ameliorates CNS autoimmunity.

Poster presentation at: ECTRIMS; September 2016; London, UK.

11. Genmab Press Release: Genmab announces completion of agreement to

transfer remaining ofatumumab rights. December 21, 2015. Accessed January

18,

2023. https://ir.genmab.com/static-files/9d491b72-bb0b-4e46-a792-dee6c29a

af7d

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Richard Jarvis +41 79 584 2326 Julie Masow +1 862 579 8456

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267 Mary Carmichael +1 862 200 8344

Marlena Abdinoor +1 617 335 9525

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Parag Mahanti +1 973 876 4912

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

April 20, 2023 01:15 ET (05:15 GMT)